RyCarma Reports First Patient Dosed in Phase 2 Surlorian Trial
RyCarma said the first patient has been dosed in its Phase 2 clinical trial of surlorian for RYR1-related myopathy.
RyCarma said the first patient has been dosed in its Phase 2 clinical trial of surlorian for RYR1-related myopathy.